On 13 October 2026, on the occasion of the adoption of the Political Declaration on Pandemic Prevention, Preparedness, and ...

On 29 September 2026 in Washington, D.C., IFPMA delivered a statement on the strategy for strengthening health emergency and ...

In this op-ed, authors argue that Europe will be among the first to confront the central question of how to ensure that ...

On 1 October 2026 in Washington, D.C., IFPMA delivered a statement on the policy on the application of data science in public ...

This op-ed argues that Japan, as the world's first super-aging society, can set a global standard for how prevention protects ...

Governments around the world are confronting increasingly common challenges: how to drive economic growth, address demographic changes and productivity pressures, and how to strengthen national ...

In this op-ed, authors argue that Europe will be among the first to confront the central question of how to ensure that ...

Scientific progress can only realize its full potential when accompanied by public confidence in the institutions, expertise and evidence that underpins it. This close-door roundtable will bring ...

Anna Puchot supports strategic communications across IFPMA’s priority policy areas. Her work includes the development of policy communications, stakeholder engagement, member-facing content, and ...

As a Standing Observer of ICH, IFPMA along with other ICH Members and Observers, has an important role in promoting global convergence toward ICH regulatory standards and their harmonized ...

This compendium of facts and figures relating to the biopharmaceutical industry and global health aims to provide a snapshot of the work this industry undertakes today. This publication examines the ...

Our Code of Practice was first drawn up in 1981, and it was the first one of its kind for any sector. Initially, correct information on the effects and side effects of medicines were at the core of ...